

ASX Announcement



9 October 2024

Notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth)

This notice is given by INOVIQ Limited ACN 009 070 384 (ASX:IIQ) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company today issued 375,000 quoted options to acquire fully paid ordinary shares at an exercise price of A1.00 per option and expiring on 8 July 2026 (**Options**) using the Company's existing placement capacity under listing rule 7.1.

The Company advises that:

- (a) the Options the subject of this notice were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meanings of sections 708A(7) and 708A(8) of the Corporations Act.

Yours faithfully

A handwritten signature in black ink, appearing to read "Mark Edwards", is written over a horizontal line.

Mark Edwards
Company Secretary
INOVIQ Limited

This document is authorised for release by the directors of INOVIQ Limited.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.